ACHV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Achieve Life Sciences Inc (ACHV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive catalysts such as analyst optimism and potential regulatory approval for cytisinicline, the lack of significant financial growth, neutral trading trends, and absence of strong proprietary trading signals suggest holding off on investment until clearer signs of growth or momentum emerge.
The technical indicators show a bullish trend with MACD positively expanding and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, RSI is in the neutral zone at 74.192, and the stock is trading near its resistance levels (R1: 4.666). There is no clear signal for a breakout or strong momentum.
Analyst rating is positive with a Buy rating and a price target of $12, indicating significant upside potential.
The inclusion of Chantix on TrumpRx removes competitive pressure and increases the likelihood of cytisinicline approval by the PDUFA date of June 20.
Financial performance remains weak with no revenue growth and a net loss of -$14.44M in Q3
No recent news or significant trading trends from hedge funds, insiders, or Congress.
High implied volatility (121.84%) suggests elevated risk.
The company's Q3 2025 financials show no revenue growth (0% YoY), a net loss of -$14.44M (improved by 15.42% YoY), and a drop in EPS to -0.28 (-22.22% YoY). Gross margin remains at 0%.
Analysts are optimistic about ACHV, with a Buy rating and a price target of $12. The removal of Chantix as a competitor is viewed as a significant positive for the company.
